Abstract
A current goal in molecular medicine is the development of new strategies for the selective inhibition of cancer-critical genes. Triplex-forming oligonucleotides and peptide nucleic acids bind to the double helix of DNA in a sequence-specific manner and with great affinity. Because of these properties, these molecules have been proposed as anti-gene therapeutic drugs. This review summarizes recent results on the use of oligonucleotides and peptide nucleic acids to downregulate gene expression in cultured cells. The data are discussed from the perspective of the recent literature on new molecular strategies with potential therapeutic applications.
Keywords: triple-helix oligonucleotides, peptide nucleic acid, antigene strategies, peg-conjugated tfo, cell cultures, oncogenes
Current Pharmaceutical Design
Title: Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Volume: 10 Issue: 7
Author(s): L. E. Xodo, S. Cogoi and V. Rapozzi
Affiliation:
Keywords: triple-helix oligonucleotides, peptide nucleic acid, antigene strategies, peg-conjugated tfo, cell cultures, oncogenes
Abstract: A current goal in molecular medicine is the development of new strategies for the selective inhibition of cancer-critical genes. Triplex-forming oligonucleotides and peptide nucleic acids bind to the double helix of DNA in a sequence-specific manner and with great affinity. Because of these properties, these molecules have been proposed as anti-gene therapeutic drugs. This review summarizes recent results on the use of oligonucleotides and peptide nucleic acids to downregulate gene expression in cultured cells. The data are discussed from the perspective of the recent literature on new molecular strategies with potential therapeutic applications.
Export Options
About this article
Cite this article as:
Xodo E. L., Cogoi S. and Rapozzi V., Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells, Current Pharmaceutical Design 2004; 10 (7) . https://dx.doi.org/10.2174/1381612043452983
DOI https://dx.doi.org/10.2174/1381612043452983 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Structural and Functional Role of Gly281 in L-asparaginase from Erwinia carotovora
Protein & Peptide Letters Thrombotic Microangiopathy and Occult Neoplasia
Cardiovascular & Hematological Disorders-Drug Targets Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation
Current Pharmaceutical Design Novel Insights in Molecular Mechanisms of CLL
Current Pharmaceutical Design Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms
Current Drug Targets Oridonin, a Promising Antitumor Natural Product in the Chemotherapy of Hematological Malignancies
Current Pharmaceutical Biotechnology HIV Shedding in Cervico-Vaginal Secretions in Pregnant Women
Current HIV Research De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
Current Pharmaceutical Design Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design Biological Basis of Novel Therapies for Myelodysplastic Syndrome
Current Cancer Therapy Reviews Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery To Be, or Not To Be: That is the Question-Lineage Commitment in Hematopoiesis
Current Immunology Reviews (Discontinued) 5-Nitro-Thiophene-Thiosemicarbazone Derivatives Present Antitumor Activity Mediated by Apoptosis and DNA Intercalation
Current Topics in Medicinal Chemistry Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Current Immunology Reviews (Discontinued) Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry Regulatory Circuitries Coordinated by Transcription Factors and microRNAs at the Cornerstone of Hematopoietic Stem Cell Self-Renewal and Differentiation
Current Stem Cell Research & Therapy